Qianjin Pharmaceutical and its subsidiary Hunan Qianjin Xiangjiang Pharmaceutical had a total of four products tentatively selected in the 12th national centralized drug procurement. The tentatively selected products include dydrogesterone tablets, iguratimod tablets, baricitinib tablets, and alogliptin benzoate tablets. The procurement cycle runs from the implementation date of the selection results until December 31, 2029. In the first quarter of 2026, Qianjin Pharmaceutical achieved revenue of 970 million yuan and net profit attributable to the parent company of 75 million yuan.
ZhuZhou QianJin Pharmaceutical Co LtdFour products tentatively selected in national procurement, securing sales volume until 2029.
Subsidiary's products tentatively selected in national procurement, boosting demand.